At last year's Research in Gerontological Nursing's annual editorial board meeting, members requested more information on how to choose high-quality outcomes for clinical trials (e.g., randomized controlled trials [RCTs] ). As measurement quality has preoccupied a lot of my professional life, I thought I would briefl y discuss what, in my opinion, makes a good outcome. In the next issue, I'll discuss qualities of poor outcome measures. A plethora of detailed information and advice has been written about each of my points. I hope that the compilation of the eight qualities that follow provides a helpful list of factors to consider when designing or evaluating research outcomes and measurement.
CLINICALLY MEANINGFUL OUTCOMES
To engage in high-quality scientifi c pursuits in gerontological health care, we need to focus clinical trial research on clinically meaningful outcomes. If an intervention yields changes in measures such as biomarkers, but fails to make an older adult feel better, function better, or survive longer, it may not be a particularly useful intervention. Clinically meaningful outcomes address what is considered important by older adults. When deciding on what is a clinically meaningful outcome, researchers need to designate an amount of change that makes the diff erence clinically meaningful. How much of a decrease in night sweats, blood pressure, or nighttime awakenings is clinically important? Minimal clinically important diff erence (MCID) is the term used to indicate the smallest difference in a measurable clinical parameter that indicates a meaningful change in a health care outcome. It can be diffi cult to determine a valid parameter of meaningful change, particularly when biomarkers are outcomes. For a biomarker to qualify as a MCID, the change in score needs to relate to another measure, such as a change in needed medication, or a patient report of improvement. Patient reports of improvement can yield biased results, and it is diffi cult to determine their validity. Another approach is to determine statistically if the change is larger than what is expected by either the random variation of the sample or the measurement error of the instrument. If an outcome that is considered important by older adults yields a lot of measurement error, another outcome may in the long run produce more valid and useful fi ndings. For example, although quality of life is considered a clinically meaningful outcome across most cancer types, a working group from the American Society of Clinical Oncology decided to measure symptoms rather than quality of life because of diffi culty measuring and interpreting even validated quality of life measures (Ellis et al., 2014) .
SENSITIVITY TO CHANGE
Clinical trials are trying to capture change. To detect the eff ect of an intervention, a measure should change in response to the treatment while remaining relatively unchanged if the treatment is not given. Methodologically, this is frequently discussed as capturing "signal" rather than "noise" or variability in the measure that is attributable to another source. Choose outcomes that are likely to change and do not have fl oor or ceiling eff ects. Stable constructs such as personality are not expected to change much or change easily. Cognitive status can be expected to change in delirium and depression but may be less likely to change as a result of an intervention for a person with Alzheimer's disease. Th e demarcations or gradients of scoring also need to be fi ne enough to detect the changes you expect.
THE PROCESS OF CHANGE
Our overreliance on measuring means from one point in time does not allow us to understand the process of change and may lead to a failure to detect an eff ect of the intervention that is present. We should not only want to understand the eff ectiveness of interventions, but also the process and time course of changes in outcomes. Analytically speaking, the process of change involves (a) the shape of the change, (b) the moderators of change, and (c) explanations for how the change occurs.
Measuring eff ects across a time-course plot shows the shape of change and can help explain the process of change. Th e duration and timing of eff ects can help us understand the timing and probability of relapse, as well dose-response relations. Outcome variables should be collected at a rate that refl ects the dynamic nature of change resulting from, for example, a physical or behavioral intervention. A trajectory of change may be linear or non-linear. Change in outcomes may be rapid early in treatment, then stabilize, and then show another shift . Hierarchical linear modeling, growth curve analysis, and simple raw data graphing with multiple time points can help uncover these patterns.
Individual diff erences that aff ect treatment outcomes are commonly called moderator variables. Moderators help us understand diff erential eff ectiveness of the treatment for certain subgroups or conditions. Understanding moderators can help target interventions to those most likely to benefi t, improve the quality of health care delivered, and save health care resources. Examples of moderator variables are social support, comorbid problems, and gender.
Oft en we infer mechanisms of action based on treatment eff ects and a theoretical framework, but this is not good enough. Treatment mechanisms allow us to understand how the intervention works to infl uence outcomes, and are exceedingly important for advancing theory, science, and the quality of health care delivered. Mediation is not the same as mechanism of action. To understand the mechanisms of action for a particular treatment, that mechanism must be measured along the time course of treatment eff ects. When treatments have multiple components and multiple causal mechanisms, the elucidation of mechanisms based on evidence can become quite thorny. To understand mechanisms of action, there must initially be a strong association between the intervention and measure of the proposed mechanism, as well as a relationship between the mechanism and outcome. Th e ability to demonstrate that there are not multiple causal paths strengthens the claim. Showing that a higher dose of the intervention increases the activation of the mediator and the eff ects also provides evidence for the mechanism of action. Replicating the results across samples, situations, and conditions, and demonstrating a logical explanation for the mechanism that is consistent with other scientifi c research, also aid acceptance of the credibility of the mechanism of action (Kazdin, 2007) .
OFF-TARGET EFFECTS
When we conceptualize an intervention, we concentrate our eff orts on measuring the outcomes to be achieved as well as sometimes measuring mediators and moderators. Consider measuring consequences that are diff erent from the intended outcome and may contribute to unintended negative consequences. Given that interventions are designed to do something, even an ineff ective intervention may be producing some off -target eff ects. People with dementia, for example, are susceptible to negative effects from too much environmental stimulation, and older adults in general have a smaller range between toxic and therapeutic doses of drugs. Measuring potential off -target mediators and outcomes may help move science forward in our understanding of eff ective interventions and mechanisms of action, and groups and subgroups most likely to benefi t from an intervention.
INTERVENTION COSTS
Limits on health care resources mandate that costs of interventions are considered relative to benefi ts. Fiscal measures are increasingly expected in RCTs. Costs include measures of the interventionist's time in planning and delivering the treatment, the assistive personnel's time spent scheduling meetings, overhead costs, as well as any additional costs of treatment. Th ere are many methodological approaches to cost-eff ectiveness analysis, and obtaining accurate data that will validly represent costs and benefi ts can be complex. Engaging health care economists on research teams is essential and also strategic for increasing the signifi cance and quality of a research proposal.
SELF-REPORT AS A GOOD MEASUREMENT IDEA
Medical and health care research has been criticized for the passive role it assigns to patients in investigating their condition. Increased eff ort has been devoted to involving patients and advocacy groups in the design of studies as well as using patient reports to evaluate treatment outcomes. Clearly, there are times when a measure of people's perceptions of their well-being, quality of life, functional ability, or pain level are more meaningful and clinically useful outcomes than objective measures. Other variables such as fatigue, emotional distress, attitudes, values, experiences, and beliefs are most directly assessed through self-report.
In 2004, the National Institutes of Health (NIH) launched an initiative to develop more measures of selfreported health. Th e resulting Patient-Reported Outcomes Measurement Information System (PROMIS) and Assessment Center is easily accessed (https://www.assessmentcenter.net/documents/InstrumentLibrary.pdf). A variety of tools for assessing physical, mental, and social health are available. One advantage of using these tools is that they may allow the researcher to better examine results across studies. A potential disadvantage in gerontology is that the tool may have been developed for all adults and thus may or may not be reliable or valid with older adult populations, or to measure specifi c geriatric outcomes.
FEASIBILITY
Feasibility is not a primary consideration, but it is necessary that the data can be obtained and that the data collection will not have unintended negative consequences on other aspects of the study. For example, a data collection method that induces stress when testing an intervention designed to reduce stress could confound results.
MARKETABLE OUTCOMES
Although the notion of choosing marketable outcomes may position science as a commodity, to conduct highquality research we must seek and obtain funding. Each funding agency or organization has a certain set of priorities and valued outcomes. For example, the NIH directs its awards to research that improves the public's health.
Biobehavioral, functional, behavioral symptom management, self-management, and cost are outcomes that are commonly applicable to gerontological RCTs.
CONCLUSION
A lot of good measurement comes down to knowing what you want to know, and how to fi nd it. Th ere is a story of the legendary drunk who lost a coin and walked under a streetlight to fi nd it. An observer said, "Th is is not where you lost it, so you won't fi nd it here. " If we are looking for an outcome that won't be found using simple superfi cial measures, we must instead use measures that off er the potential of capturing real change as a result of an intervention.
